Observations placeholder
Pulmozyme
Identifier
019982
Type of Spiritual Experience
Background
A description of the experience
Dornase alfa (proprietary name Pulmozyme ) is a highly purified solution of recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. Dornase alfa hydrolyzes the DNA present in sputum/mucus of cystic fibrosis patients and reduces viscosity in the lungs, promoting improved clearance of secretions. This protein therapeutic agent is produced in Chinese hamster ovary cells.
Cystic fibrosis
Dornase alfa is the most recent therapeutic agent developed with this basic mechanism of action. Prior to the cloning of the human enzyme, bovine DNase I was on the market for many years, though its utility was limited by the inherent antigenic response to a cow protein in the lungs of patients. Other DNases, such as DNase II, have therapeutic potential as well, but no further DNases have been brought to market yet for cystic fibrosis.
Dornase alfa is an orphan drug.
On Jan, 09, 2017 3,249 people reported to have side effects when taking Pulmozyme.
Among them, 4 people (0.12%) have Hallucination
On Feb, 5, 2016: 1,232 people reported to have side effects when taking Pulmozyme. Among them, 91 people (7.39%) have Death.
Time on Pulmozyme when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 0.00% | 0.00% | 50.00% | 50.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Pulmozyme :
| Female | Male | |
| Death | 40.45% | 59.55% |
Age of people who have Death when taking Pulmozyme :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 3.57% | 0.00% | 28.57% | 21.43% | 25.00% | 3.57% | 3.57% | 14.29% |
Top conditions involved for these people :
- Cystic fibrosis (34 people, 37.36%)
- Cystic fibrosis pancreatic (17 people, 18.68%)
- Pleural infection (5 people, 5.49%)
- Bone disorder (2 people, 2.20%)
- Tetralogy of fallot repair (1 people, 1.10%)